Breast Cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: During chemotherapy with anthracyclines, they will receive 10 mg of empagliflozin daily for 12 weeks. Intervention 2: Control group: During chemotherapy with anthra
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
19 Years to No maximum
Inclusion criteria
Inclusion criteria: Human epidermal growth factor receptor 2-negative, nonmetastatic breast cancer requiring adjuvant or neoadjuvant therapy The patient's functional status and general well-being score ranged from 0 to 2 Candidate for anthracycline-based chemotherapy regimen Having consent to participate in the study
Exclusion criteria
Exclusion criteria: History of chemotherapy or radiotherapy in the past History of heart failure Left Ventricular Ejection Fraction less than 50% History of moderate to severe valvular heart disease Pregnancy and breastfeeding Symptomatic hypotension or systolic blood pressure less than 100 mmHg History of myocardial infarction or coronary artery disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in echocardiographic indicators: Left ventricular ejection fraction, maximum shortening of the left ventricular length during systole compared to its length during diastole, left ventricular end-systolic volume, left ventricular end-diastolic volume, left ventricular filling pressure assessment index, mitral flow, tension and change in tension of the left and right ventricular walls. Timepoint: Before chemotherapy and 12 weeks after starting chemotherapy. Method of measurement: 3DTDI echocardioghrafic. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of empagliflozin. Timepoint: During treatment. Method of measurement: Clinical examination, questioning the patient and, if necessary, performing tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbbas Moradi
Hamedan University of Medical Sciences
Outcome results
None listed